CD19 and systemic lupus erythematosus: Initial clinical data from seven patients with refractory SLE treated with CD19 CAR T-cells showed significant reductions in disease activity and autoantibody levels, with no relapses observed during long-term follow-up, indicating a favorable safety profile [95].